source
- Amgen expands crackdown on what it says is misuse of 340B programAmgen is expanding its claims data requirements for pharmacies dispensing its drugs under the 340B federal drug discount program. The company said the new policy addresses what it claims is fraud a…Endpoints · 2mo ago↗ source
- FDA Approves Adjuvant Atezolizumab for MRD+ Muscle-Invasive Bladder CancerThe FDA approved adjuvant atezolizumab for muscle-invasive bladder cancer with circulating tumor DNA molecular residual disease.onclive · 2mo ago↗ source
- Detalimogene Voraplasmid Yields 54% CR Rate in Heavily Pretreated BCG-Unresponsive NMIBC With CISTRAEs were generally reversible and low grade, and 96.8% of patients remained free from progression to T2 or greater disease at the data cutoff.